GlassScriptPhysician profile
Michelle R Dickens
NPI 1861506610
$59,011.20
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11K · 2022: $39K · 2023: $9,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,800 · Food and Beverage: $825 · Travel and Lodging: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,800.00 |
| Food and Beverage | $824.82 |
| Travel and Lodging | $706.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $54,444.97 | 2021-2023 | Fasenra, Evusheld, Tezspire |
| Glaxosmithkline, LLC. | $643.02 | 2021-2023 | Nucala |
| Genzyme Corporation | $586.51 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $493.07 | 2021-2023 | Takhzyro, Cuvitru |
| Csl Behring | $430.67 | 2021-2023 | Haegarda |
| Pfizer INC. | $399.42 | 2021-2022 | |
| Amgen INC. | $321.94 | 2021-2023 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.62 | 2021-2022 | |
| Genentech USA, INC. | $213.42 | 2021-2023 | Xolair |
| Blueprint Medicines Corporation | $203.33 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $201.80 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $146.45 | 2021-2022 | |
| Grifols USA, LLC | $126.74 | 2021-2023 | Xembify |
| Alk-Abello, INC | $103.99 | 2021-2023 | Odactra, Ragwitek, Grastek |
| Genentech, INC. | $85.91 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $83.10 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $73.79 | 2022-2023 | |
| Optinose US, INC. | $51.39 | 2021-2022 | |
| Incyte Corporation | $46.17 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $40.30 | 2022 | |
| Pharming Healthcare, INC. | $38.57 | 2021-2022 | |
| Horizon Therapeutics Plc | $19.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Dickens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.